有机化学 ›› 2018, Vol. 38 ›› Issue (4): 871-882.DOI: 10.6023/cjoc201711007 上一篇    下一篇

研究论文

新型Rho激酶抑制剂的设计、合成及生物活性评价

姚阳阳a, 刘晓宇a, 杨飞龙a, 杨颖a, 袁天翊b, 方莲花b, 杜冠华b, 焦晓臻a, 谢平a   

  1. a 中国医学科学院&北京协和医学院药物研究所 天然药物活性物质与功能国家重点实验室 活性物质发现与适药化研究北京市重点实验室 北京 100050;
    b 中国医学科学院&北京协和医学院药物研究所 天然药物活性物质与功能国家重点实验室 药物靶点研究与 新药筛选北京市重点实验室 北京 100050
  • 收稿日期:2017-11-03 修回日期:2017-11-24 发布日期:2017-12-05
  • 通讯作者: 焦晓臻, 谢平 E-mail:jiaoxz@imm.ac.cn;xp@imm.ac.cn
  • 基金资助:

    中国医学科学院医学与健康科技创新工程资助项目(No.2016-I2M-3-009)、中国医学科学院、北京协和医学院“中央级公益性科研院所基本科研业务费”(No.2016ZX350024)资助项目.

Design, Synthesis and Biological Activity Evaluation of Novel Rho Kinase Inhibitors

Yao Yangyanga, Liu Xiaoyua, Yang Feilonga, Yang Yinga, Yuan Tianyib, Fang Lianhuab, Du Guanhuab, Jiao Xiaozhena, Xie Pinga   

  1. a State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050;
    b State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050
  • Received:2017-11-03 Revised:2017-11-24 Published:2017-12-05
  • Contact: 10.6023/cjoc201711007 E-mail:jiaoxz@imm.ac.cn;xp@imm.ac.cn
  • Supported by:

    Project supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. CIFMS 2016-I2M-3-009) and the Fun-damental Research Funds for Chinese Academy of Medical Sciences (CAMS)/Peking Union Medical College (PUMC) (No. 2016ZX350024).

以前期结构优化得到的Rho激酶I(ROCK I)抑制剂N-(1H-吲唑-5-基)-1-(4-甲基苄基)吡咯-3-酰胺(I)为先导结构,采用拼接原理,设计合成16个新型含取代的四氢嘧啶-2-酮结构的吲唑类衍生物,并经1H NMR,13C NMR和HRMS确证目标产物的结构.生物活性结果显示,1-(1H-吲唑-5-基)-3-(4-硝基苯基)四氢嘧啶-2(1H)酮(8a)和4-(3-(1H-吲唑-5-基)-2氧四氢嘧啶-1(2H)-基)苯甲腈(8b)具有较好的ROCK I抑制活性,IC50值分别为6.01和9.46 μmol·L-1;离体实验显示化合物8a8b具有较好的舒张脑基底膜动脉的活性,EC50值分别为15.92和20.61 μmol·L-1.

关键词: Rho相关激酶, 心脑血管疾病, 四氢嘧啶-2-酮类衍生物, 抑制剂

Based on the structure of N-(1H-indazol-5-yl)-1-(4-methylbenzyl) pyrrolidine-3-carboxamide (I), which was previously obtained via a structure-based optimization of ROCK 1 inhibitor, sixteen novel 1-substituted-(1H-indazol-5-yl)tetrahydro pyrimidin-2(1H)-one derivatives were designed and synthesized via an active substructure combination strategy. The structures of the target compounds were confirmed by 1H NMR, 13C NMR and HRMS. The bioassay data indicated that 1-(1H-indazol-5-yl)-3-(4-nitrophenyl) tetrahydropyrimidin-2(1H)-one (8a) and 4-(3-(1H-indazol-5-yl)-2-oxo tetrahydropyrimidin-1(2H)-yl)benzonitrile (8b) had good activities against ROCK I. The IC50 values for 8a and 8b were 6.01 and 9.46 μmol·L-1, respectively. Moreover, ex vivo studies demonstrated that 8a and 8b exhibited vasorelaxant activity in rat basilar artery ring. The EC50 values for 8a and 8b were 15.92 and 20.61 μmol·L-1, respectively.

Key words: Rho-associated kinase, cardio-cerebrovascular disease, tetrahydro pyrimidin-2(1H)-one derivative, inhibitor